Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.

The difference between groups in LS-BMD remained statistically significant after accounting for almost all confounders (p=0.045 adjusted for age; p=0.024 adjusted for disease duration; p=0.047 adjusted for HCeq dose; p=0.047 adjusted for 25(OH)D; p=0.008 adjusted for HbA1c), with the exception of current treatment duration, for which a borderline significance was nevertheless observed (p=0.052) ( Table 2 ).

also in 7,017 other papers